Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
You may also be interested in...
Harvard Drug Continues Expansion With Watson’s Rugby OTC Business
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.
Harvard Drug Continues Expansion With Watson’s Rugby OTC Business
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.
In Brief
Watson prevails in Mucinex patent ruling